04Jun
Cannabis-Derived Ingredients in FDA-Regulated Products: More Questions than Answers at FDA’s May 2019 Public Hearing
As most folks with any interest in the burgeoning cannabidiol (CBD) industry likely know, on May 31, 2019, the Food and Drug Administration held a public hearing “to obtain scientific data and information about the safety, manufacturing, product...
By:
Mintz - Consumer Product Safety Viewpoints
Related
Last week, the EEOC announced that it does not intend to renew its request for authorization to coll...
Read More >
The coronavirus pandemic has upended nearly every corner of the world — and shareholder activism is...
Read More >
In This Issue. The Securities and Exchange Commission (SEC) adopted a rule permitting most exchange-...
Read More >
Join us for an in-depth conversation with top attorneys from Duane Morris LLP, Fenton Grant Mayfield...
Read More >
In September, the Treasury Department issued final regulations governing hardship withdrawals from 4...
Read More >
Earlier this month, Governor Pritzker signed into law SB 1557, revising the Recreational Cannabis La...
Read More >